Celgene Corporation – Product Pipeline Review

Global Markets Direct’s, ‘Celgene Corporation – Product Pipeline Review – 2016’, provides an overview of the Celgene Corporation’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Celgene Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Celgene Corporation

The report provides overview of Celgene Corporation including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Celgene Corporation’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Celgene Corporation’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Celgene Corporation’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Celgene Corporation

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Celgene Corporation’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Celgene Corporation Snapshot 6

Celgene Corporation Overview 6

Key Information 6

Key Facts 6

Celgene Corporation - Research and Development Overview 7

Key Therapeutic Areas 7

Celgene Corporation - Pipeline Review 15

Pipeline Products by Stage of Development 15

Pipeline Products - Monotherapy 16

Pipeline Products - Partnered Products 17

Pipeline Products - Out-Licensed Products 20

Celgene Corporation - Pipeline Products Glance 22

Celgene Corporation - Late Stage Pipeline Products 22

Celgene Corporation - Clinical Stage Pipeline Products 24

Celgene Corporation - Early Stage Pipeline Products 26

Celgene Corporation - Drug Profiles 28

apremilast 28

lenalidomide 31

azacitidine 36

CC-90007 40

mongersen 43

paclitaxel albumin bound 44

pomalidomide 48

romidepsin 53

amrubicin hydrochloride 56

CC-11050 58

CC-220 59

GI-6207 61

GI-6301 63

PDA-002 64

spebrutinib besylate 65

Stem Cell Therapy for Hematological Malignancies, Non-Malignant Disorders and Hypoxic-ischemic Encephalopathy 67

CC-122 68

CC-223 70

PNK-007 71

CC-115 72

CC-90001 73

CC-90002 74

CC-90003 75

CC-90005 76

Cellular Immunotherapy to Target GD2 for Neuroblastoma 77

CTP-730 78

pinometostat 79

AVL-181 81

AVL-192 82

CC-0730671 83

CC-2142 84

CC-509 85

CC-539 86

Monoclonal Antibody 1 for Inflammation 87

Monoclonal Antibody 2 for Inflammation 88

Small Molecules for Undisclosed Indication 89

Small Molecules to Agonize ROR gamma for Breast Cancer 90

Antibody for Oncology 92

Antibody for Undisclosed Indication 93

CC-0739623 94

CC-2141 95

CC-90006 96

CC-90008 97

CC-90009 98

CC-90010 99

CC-90011 100

CSC-1 101

Drug for Hematological Disorders and Oncology 102

Drug to Inhibit Kinase for Inflammation 103

Drugs for Hematology and Oncology 104

Monoclonal Antibody Conjugate to Inhibit Protein S100-A9 for MDS 105

Small Molecule to Inhibit Brutons Tyrosine Kinase for Inflammation 106

Small Molecules for Inflammation 107

Small Molecules for Inflammation and Cancer 108

Small Molecules for Malaria 109

Celgene Corporation - Pipeline Analysis 110

Celgene Corporation - Pipeline Products by Target 110

Celgene Corporation - Pipeline Products by Route of Administration 112

Celgene Corporation - Pipeline Products by Molecule Type 113

Celgene Corporation - Pipeline Products by Mechanism of Action 114

Celgene Corporation - Recent Pipeline Updates 116

Celgene Corporation - Dormant Projects 157

Celgene Corporation - Discontinued Pipeline Products 160

Discontinued Pipeline Product Profiles 160

Celgene Corporation - Company Statement 161

Celgene Corporation - Locations And Subsidiaries 162

Head Office 162

Other Locations & Subsidiaries 162

Appendix 168

Methodology 168

Coverage 168

Secondary Research 168

Primary Research 168

Expert Panel Validation 168

Contact Us 168

Disclaimer 169

List of Tables

List of Tables

Celgene Corporation, Key Information 10

Celgene Corporation, Key Facts 10

Celgene Corporation – Pipeline by Indication, 2016 12

Celgene Corporation – Pipeline by Stage of Development, 2016 19

Celgene Corporation – Monotherapy Products in Pipeline, 2016 20

Celgene Corporation – Partnered Products in Pipeline, 2016 21

Celgene Corporation – Partnered Products/ Combination Treatment Modalities, 2016 22

Celgene Corporation – Out-Licensed Products in Pipeline, 2016 24

Celgene Corporation – Out-Licensed Products/ Combination Treatment Modalities, 2016 25

Celgene Corporation – Pre-Registration, 2016 26

Celgene Corporation – Phase III, 2016 27

Celgene Corporation – Phase II, 2016 28

Celgene Corporation – Phase I, 2016 29

Celgene Corporation – Preclinical, 2016 30

Celgene Corporation – Discovery, 2016 31

Celgene Corporation – Pipeline by Target, 2016 114

Celgene Corporation – Pipeline by Route of Administration, 2016 116

Celgene Corporation – Pipeline by Molecule Type, 2016 117

Celgene Corporation – Pipeline Products by Mechanism of Action, 2016 118

Celgene Corporation – Recent Pipeline Updates, 2016 120

Celgene Corporation – Dormant Developmental Projects,2016 161

Celgene Corporation – Discontinued Pipeline Products, 2016 164

Celgene Corporation, Other Locations 166

Celgene Corporation, Subsidiaries 166

List of Figures

List of Figures

Celgene Corporation – Pipeline by Top 10 Indication, 2016 12

Celgene Corporation – Pipeline by Stage of Development, 2016 19

Celgene Corporation – Monotherapy Products in Pipeline, 2016 20

Celgene Corporation – Partnered Products in Pipeline, 2016 21

Celgene Corporation – Out-Licensed Products in Pipeline, 2016 24

Celgene Corporation – Pipeline by Top 10 Target, 2016 114

Celgene Corporation – Pipeline by Route of Administration, 2016 116

Celgene Corporation – Pipeline by Molecule Type, 2016 117

Celgene Corporation – Pipeline Products by Top 10 Mechanism of Action, 2016 118

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports